A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia Full Text
Archives of Pharmacal Research, 06/21/2012
Yang SH et al. – The EPO–hyFc showed higher in vitro and in vivo bioactivities than EPOIgG1 Fc and highly glycosylated EPO (Aranesp). Phase I clinical trial with EPO–hyFc is currently undergoing in Korea.